Business Description
Caribou Biosciences Inc
NAICS : 541713
SIC : 2833
ISIN : US1420381089
Share Class Description:
CRBU: Ordinary SharesTotal Employee Number:
97Description
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 4.37 | |||||
Equity-to-Asset | 0.69 | |||||
Debt-to-Equity | 0.26 | |||||
Debt-to-EBITDA | -0.23 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | -5.62 | |||||
Beneish M-Score | -3.58 | |||||
WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -19.5 | |||||
3-Year EBITDA Growth Rate | 6.3 | |||||
3-Year EPS without NRI Growth Rate | 6 | |||||
3-Year FCF Growth Rate | 9.3 | |||||
3-Year Book Growth Rate | -36.1 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 43.36 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 30.29 | |||||
9-Day RSI | 41.3 | |||||
14-Day RSI | 43.81 | |||||
3-1 Month Momentum % | -24.76 | |||||
6-1 Month Momentum % | -0.93 | |||||
12-1 Month Momentum % | -6.18 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 6.22 | |||||
Quick Ratio | 6.22 | |||||
Cash Ratio | 5.98 | |||||
Days Sales Outstanding | 4.54 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -16 | |||||
Shareholder Yield % | -3.43 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -1067.22 | |||||
Net Margin % | -1189.14 | |||||
EBITDA Margin % | -1039.29 | |||||
FCF Margin % | -907.26 | |||||
OCF Margin % | -903.78 | |||||
ROE % | -88.88 | |||||
ROA % | -65.7 | |||||
ROIC % | -253.48 | |||||
3-Year ROIIC % | 32.64 | |||||
ROC (Joel Greenblatt) % | -445.49 | |||||
ROCE % | -67.67 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 14.59 | |||||
PB Ratio | 1.67 | |||||
Price-to-Tangible-Book | 1.67 | |||||
EV-to-EBIT | -0.69 | |||||
EV-to-EBITDA | -0.71 | |||||
EV-to-Revenue | 7.4 | |||||
EV-to-Forward-Revenue | 7.91 | |||||
EV-to-FCF | -0.82 | |||||
Price-to-GF-Value | 1.04 | |||||
| Price-to-Net-Current-Asset-Value | 2.24 | |||||
| Price-to-Net-Cash | 2.4 | |||||
Earnings Yield (Greenblatt) % | -144.93 | |||||
FCF Yield % | -58.56 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:CRBU
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Caribou Biosciences Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 11.203 | ||
| EPS (TTM) ($) | -1.42 | ||
| Beta | 3.4232 | ||
| 3-Year Sharpe Ratio | 0.09 | ||
| 3-Year Sortino Ratio | 0.15 | ||
| Volatility % | 89.88 | ||
| 14-Day RSI | 43.81 | ||
| 14-Day ATR ($) | 0.141627 | ||
| 20-Day SMA ($) | 1.75275 | ||
| 12-1 Month Momentum % | -6.18 | ||
| 52-Week Range ($) | 1.38 - 3.535 | ||
| Shares Outstanding (Mil) | 99.18 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Caribou Biosciences Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Caribou Biosciences Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-12 | In 120 days | ||
| Second quarter earnings results for 2026 | 2026-08-12 | In 28 days | ||
| H.C. Wainwright 4th Annual Cell Therapy Virtual Conference | 2026-06-30 10:00 | 1.77 (+4.12%) | ||
| General meeting for 2026 | 2026-06-17 07:30 | 1.69 (+1.81%) | ||
| Guidance call for 2026 | 2026-06-04 14:35 | 2.00 (-12.66%) | ||
| H.C. Wainwright 4th Annual BioConnect Investor Conference | 2026-05-19 12:30 | 2.07 (-4.17%) | ||
| Guidance call for 2026 | 2026-05-13 08:40 | 2.03 (-0.49%) | ||
| First quarter earnings results for 2026 | 2026-05-07 | 1.95 (+0.00%) | ||
| Guidance call for 2026 | 2026-03-10 08:00 | 1.97 (+10.06%) | ||
| Annual report for 2025 | 2026-03-05 | 1.80 (+1.12%) |
Show
Entries
Caribou Biosciences Inc Frequently Asked Questions
What is Caribou Biosciences Inc(CRBU)'s stock price today?
The current price of CRBU is $1.75. The 52 week high of CRBU is $3.54 and 52 week low is $1.38.
When is next earnings date of Caribou Biosciences Inc(CRBU)?
The next earnings date of Caribou Biosciences Inc(CRBU) is 2026-08-12 Est..
Does Caribou Biosciences Inc(CRBU) pay dividends? If so, how much?
Caribou Biosciences Inc(CRBU) does not pay dividend.
Guru Commentaries on NAS:CRBU
No articles.
Press Release
Articles on Caribou Biosciences Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers